Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Fineline Cube Feb 14, 2026
Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Fineline Cube Feb 14, 2026
Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Fineline Cube Feb 14, 2026
Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026
Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis

Fineline Cube Feb 14, 2026
Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Fineline Cube Feb 13, 2026
Company Deals

Azenta Life Sciences and Vazyme Biotech Form Global Partnership for Comprehensive Services

Fineline Cube May 23, 2023

Azenta Life Sciences (NASDAQ: AZTA) has entered into a global partnership with China-based Vazyme Biotech...

Company Drug

3SBio Inc. Initiates Phase III Clinical Study for Thrombopoietin in Chronic Liver Disease Patients

Fineline Cube May 23, 2023

China-based 3SBio Inc. (HKG: 1530) has announced the enrollment of the first patient in a...

Company Drug

Shanghai Junshi Biosciences’ Tuoyi Combo for Triple Negative Breast Cancer Accepted for Review

Fineline Cube May 23, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that the regulatory authorities...

Company Drug

Oculis’ OCS-01 Achieves Primary Efficacy Endpoint in Phase III DIAMOND Trial for DME

Fineline Cube May 23, 2023

US-based Oculis Holding AG (NASDAQ: OCS) has announced positive top-line results from Stage 1 of...

Company Deals

Nona Biosciences and ModeX Therapeutics Partner to Develop Polyspecific Antibodies

Fineline Cube May 23, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Policy / Regulatory

NHSA Proposes Draft to Enhance Basic Medical Insurance Payment Management for Consumables

Fineline Cube May 23, 2023

The National Healthcare Security Administration (NHSA) has issued a Notice seeking public feedback on draft...

Company Drug

SinoMab BioScience’s SM17 IND Accepted by NMPA for Potential Global First-in-Class Monoclonal Antibody

Fineline Cube May 23, 2023

Hong Kong-based biotech SinoMab BioScience Ltd (HKG: 3681) has announced that the National Medical Products...

Policy / Regulatory

China Aims to Establish Basic Elderly Care System by 2025, Outlines Comprehensive Plan

Fineline Cube May 23, 2023

The General Office of the CPC Central Committee and General Office of the State Council...

Company Deals

JW Therapeutics Secures Supply Agreement with Juno to Advance CAR-T Therapy Commercialization

Fineline Cube May 22, 2023

China-based JW Therapeutics (HKG: 2126) has announced a carrier supply agreement with its shareholder Juno,...

Company Drug

HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study

Fineline Cube May 22, 2023

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...

Company Deals

GenScript Biotech’s Legend Biotech Secures Private Placement with Hillhouse Investment

Fineline Cube May 22, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has revealed that its subsidiary,...

Company Drug

Zhejiang Conba Pharmaceutical’s Inhalable Pirfenidone for IPF Clears for Chinese Clinical Trials

Fineline Cube May 22, 2023

Zhejiang Conba Pharmaceutical Co., Ltd (SHA: 600572) has announced that its modified version of US...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Two Autoimmune Disease Drug Candidates

Fineline Cube May 22, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has separately announced clinical trial approvals from the National...

Company Drug

Sino-US Laekna Receives FDA Clearance for LAE102 Clinical Trial in NSCLC

Fineline Cube May 22, 2023

Sino-US Laekna has announced that it has received clinical trial clearance from the US Food...

Policy / Regulatory

Beijing Hospitals to Pilot DRG-VBP Reforms for Medical Consumables Procurement

Fineline Cube May 22, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that six hospitals in...

Company

Lundbeck A/S Reports Record Quarterly Revenue in Q1 2023 with 11% YOY Increase

Fineline Cube May 22, 2023

Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) has released its financial report for the first...

Company Drug

Cabaletta Bio’s CABA-201 Clears FDA for Phase I/II Study in Idiopathic Inflammatory Myopathy

Fineline Cube May 19, 2023

US-based Cabaletta Bio, Inc. (NASDAQ: CABA) has announced that the US Food and Drug Administration...

Company Deals

MicroPort Scientific Plans IPO for Subsidiary MicroPort CRM on Hong Kong Stock Exchange

Fineline Cube May 19, 2023

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced its intention to spin...

Company Deals

Mustang Bio, Inc. Enters Strategic Partnership with uBriGene for Cell and Gene Therapy

Fineline Cube May 19, 2023

US-based Mustang Bio, Inc. has announced a strategic partnership with uBriGene (Boston) Biosciences Inc., the...

Company Deals

Beijing Sun-Novo Secures Exclusive Rights to Kaneka’s Skin Patch Drugs in Licensing Deal

Fineline Cube May 19, 2023

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with...

Posts pagination

1 … 482 483 484 … 625

Recent updates

  • Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology
  • VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline
  • Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY
  • Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31
  • 3SBio’s Amdokitug Wins NMPA Approval for Moderate-to-Severe Plaque Psoriasis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Siemens Healthineers Deepens Mayo Clinic Partnership on AI Neurology and Precision Oncology

Company Deals

VivaVision Biotech Files Hong Kong IPO to Advance Ophthalmology Pipeline

Medical Device

Astellas’ VENTANA CLDN18 Assay Wins NMPA Approval as First Companion Diagnostic for VYLOY

Company Deals

Genhouse Bio Partners with Gilead on $1.5 Billion Synthetic Lethal Cancer Project GH31

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.